BioAdaptives Announces Board and Compensation Changes
Ticker: BDPT · Form: 8-K · Filed: Feb 7, 2025 · CIK: 1575142
| Field | Detail |
|---|---|
| Company | Bioadaptives, INC. (BDPT) |
| Form Type | 8-K |
| Filed Date | Feb 7, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation
Related Tickers: BDPT
TL;DR
BioAdaptives shakes up board & exec pay. Big changes coming?
AI Summary
BioAdaptives, Inc. announced on February 3, 2025, a change in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors and the election of new ones, alongside adjustments to compensatory plans.
Why It Matters
Changes in leadership and compensation can signal shifts in company strategy or financial health, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in directors and officers, especially without detailed reasons, can introduce uncertainty about the company's future direction and stability.
Key Players & Entities
- BIOADAPTIVES, INC. (company) — Registrant
- February 3, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 2620 Regatta Drive, Suite 102, Las Vegas, Nevada 89128 (address) — Principal Executive Office
- (702) 659-8829 (phone_number) — Registrant's telephone number
FAQ
What specific reasons were given for the departure of directors or certain officers?
The filing does not specify the reasons for the departure of directors or certain officers, only that these events occurred.
Who are the newly elected directors or appointed officers?
The filing indicates the election of directors and appointment of officers but does not name the individuals involved in this specific section.
What are the details of the compensatory arrangements for the officers?
The filing mentions compensatory arrangements of certain officers but does not provide specific details within the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 3, 2025.
What is the principal executive office address for BioAdaptives, Inc.?
The principal executive office address for BioAdaptives, Inc. is 2620 Regatta Drive, Suite 102, Las Vegas, Nevada 89128.
Filing Stats: 348 words · 1 min read · ~1 pages · Grade level 9 · Accepted 2025-02-07 16:36:38
Filing Documents
- bdpt_8k.htm (8-K) — 18KB
- bdpt_ex991a.htm (EX-99.1A) — 10KB
- bdpt_ex991b.htm (EX-99.1B) — 8KB
- bdpt_8kimg4.jpg (GRAPHIC) — 5KB
- bdpt_ex991aimg1.jpg (GRAPHIC) — 5KB
- bdpt_ex991bimg1.jpg (GRAPHIC) — 5KB
- 0001640334-25-000210.txt ( ) — 181KB
- bdpt-20250203.xsd (EX-101.SCH) — 6KB
- bdpt-20250203_lab.xml (EX-101.LAB) — 13KB
- bdpt-20250203_cal.xml (EX-101.CAL) — 1KB
- bdpt-20250203_pre.xml (EX-101.PRE) — 8KB
- bdpt-20250203_def.xml (EX-101.DEF) — 2KB
- bdpt_8k_htm.xml (XML) — 3KB
02. Appointments of Mr. Mark Frissora to Board of Directors and Mr. Reed Harris to Advisory Board
Item 5.02. Appointments of Mr. Mark Frissora to Board of Directors and Mr. Reed Harris to Advisory Board On February 3, 2025 , the Company appointed Mr. Mark Frissora to its Board of Directors. A press release was issued to this effect, which is incorporated by reference to 99.1a to this Current Report on Form 8-K. On February 6, 2025, the Company appointed Mr. Reed Harris to its Advisory Board. A press release was issued to this effect, which is incorporated by reference to 99.1b to this Current Report on Form 8K.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1a Press Release dated February 3, 2025 99.1b Press Release dated February 6. 2025 2 SIGNATURE Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. February 7, 2025. BioAdaptives, Inc. /s/ James Keener James Keener, CEO 3